Page 3 - ஃபைசர் உலகளாவிய ப்ராடக்ட் வளர்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஃபைசர் உலகளாவிய ப்ராடக்ட் வளர்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஃபைசர் உலகளாவிய ப்ராடக்ட் வளர்ச்சி Today - Breaking & Trending Today

Pfizer (PFE) Announces Real-World Evidence Supports Effectiveness of First-line IBRANCE Combination Therapy in HR+, HER2- Metastatic Breast Cancer

Pfizer Inc.: EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency


(2)
- If approved, somatrogon will serve as a once-weekly treatment option -
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for somatrogon, a long-acting recombinant human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD). Pfizer expects a decision from the European Commission in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210226005102/en/
Today s announcement is an example of our decades-long commitment to actively support the pediatric growth hormone deficiency community through therapeutic options that help children reach their full potential, said Brenda Cooperstone, MD, Chief Development Officer, Rare Disease, Pfizer Global Product Development. If approved in t ....

United States , Andrew Widger , Chuck Triano , Phillip Frost , Brenda Cooperstone , European Commission , Pfizer Global Product Development , Health Inc , Exchange Commission , Pfizer Inc , European Medicines Agency , Marketing Authorization Application , Chief Development Officer , Rare Disease , Pfizer Global Product , Orphan Drug , Annual Reports , Looking Information , Factors That May Affect Future , Statement Regarding Forward Looking , ஒன்றுபட்டது மாநிலங்களில் , பிலிப் பனி , ஐரோப்பிய தரகு , ஃபைசர் உலகளாவிய ப்ராடக்ட் வளர்ச்சி , ஆரோக்கியம் இன்க் , பரிமாற்றம் தரகு ,

Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab


Date Time
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma. The study evaluates the efficacy and safety of elranatamab, administered subcutaneously, in patients with disease that is refractory to at least one agent in each of three major classes of medications approved for multiple myeloma. The study’s estimated primary completion date is June 2022. ....

United States , Alexanderm Lesokhin , Susie Novis Durie , Chris Boshoff , Pfizer Inc , International Myeloma Foundation , Drug Administration , Pfizer Global Product Development , Virtual American Society Of Hematology , Memorial Sloan Kettering Cancer Center , Fast Track Designation , Fast Track , Chief Development Officer , Pfizer Global Product , Virtual American Society , Annual Meeting , Memorial Sloan Kettering Cancer , International Myeloma , Immune Response , ஒன்றுபட்டது மாநிலங்களில் , ஃபைசர் இன்க் , சர்வதேச மைலோமா அடித்தளம் , ஃபைசர் உலகளாவிய ப்ராடக்ட் வளர்ச்சி , மெய்நிகர் அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி , நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் , வேகமாக டிராக் பதவி ,